Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology
用于“See”的三峰聚合物胶束
基本信息
- 批准号:8298518
- 负责人:
- 金额:$ 17.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-07 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisApoptoticBedsBiocompatibleBloodCaliberClinical TrialsColon CarcinomaCoupledDiseaseDrug Delivery SystemsDrug KineticsDyesEthylene GlycolsExcisionFluorescenceGenerationsGoalsGossypolHumanImageImageryIn VitroLasersLightLungMalignant NeoplasmsMalignant neoplasm of pancreasMalignant neoplasm of prostateMicellesMicroscopicModalityModelingMorbidity - disease rateMusNanotechnologyNeuroblastomaOperative Surgical ProceduresOpticsPalpablePalpationPatientsPenetrationPermeabilityPharmaceutical PreparationsPhotochemotherapyPhotosensitizing AgentsProceduresProteinsRadiationResearchSeriesSinglet OxygenSolid NeoplasmSurgeonSurgical OncologySurgical marginsTarsTestingTherapeuticTimeTissuesTranslationsVisualbasecancer cellcaprolactonecell killingchemotherapycost effectiveethylene glycolimaging modalityimprovedin vivoinhibitor/antagonistinsightintravenous injectionkillingslight effectsmalignant breast neoplasmmimeticsmouse modelnanocarriernanoparticleneoplastic cellnoveloptical imagingresearch studytumor
项目摘要
DESCRIPTION (provided by applicant): The major goal of surgical oncology is the complete resection of tumors with adequate tumor-free margins and minimal surgical morbidity, noting that surgery cures about 45% of patients, whereas chemotherapy and radiation cure only 5% of patients. In lung, breast, prostate, colon, and pancreatic cancers, a complete resection of tumors has a 3- to 5-fold increase in survival over partial or incomplete surgical resection. However, the intraoperative assessment of tumor margins is merely based on palpation and visual inspection, resulting frequently in incomplete tumor resection (R1 resections). The goal is to develop nanotechnology for "see and treat" modalities in surgical oncology, enabled by polymeric micelles that emit tissue penetrating near-infrared light for delineation of tumor margins and surgical guidance; generate singlet oxygen upon intra- operative photodynamic therapy (PDT); and enhance cancer cell apoptosis by the co-delivery of gossypol, a natural BH3 mimetic that inhibits anti-apoptotic Bcl-2 proteins: Bcl-2, Bcl-xL, and Mcl-1. We have proven that poly(ethylene glycol)-block-poly(e-caprolactone) (PEG-b-PCL) assembles into nanoparticles that entrain a near-infrared dye (DiR), a photosensitizer (mTHPP), and gossypol, forming micelles that are 100 nm in diameter and slowly release all 3 components over 24 hrs. We hypothesize that PEG-b-PCL micelles filled with DiR, mTHPP, and gossypol will accumulate at solid tumors via the enhanced permeability and retention effect and "light up" tumor margins, enabling surgical guidance, more complete surgical resection, and lower tumor reoccurrence. We hypothesize that laser light delivered to the "lit up" region of the tumor bed (intraoperative PDT) will generate singlet oxygen that kills tumor cells, especially in concert with co-delivered gossypol. Specific Aims: (1) To assess the stability, generation of singlet oxygen, and tumor targeting of PEG-b-PCL micelles filled with DiR, mTHPP, and gossypol by in vitro physicochemical and photophysical studies and in vivo experiments: whole body optical imaging of DiR and mTHPP and a pharmacokinetics study on gossypol. (2). To assess tumor reoccurrence after surgical guidance by PEG-b-PCL micelles filled with DiR and surgical resection of tumors and after surgical resection of tumors alone as a positive control. (3). To assess tumor reoccurrence after surgical resection and intraoperative PDT with PEG-b-PCL micelles filled with mTHPP, with or without co-incorporated gossypol. (4). To assess tumor reoccurrence after optical imaging of DiR, surgical resection, and intraoperative PDT with mTHPP and gossypol (tri-modal therapy). Advances in integrated optical imaging and therapeutic capability of biocompatible PEG-b-PCL micelles will enable tenable nano-technology applications in surgical oncology and rapid translation into clinical trials.
描述(由申请人提供):肿瘤外科的主要目标是完全切除肿瘤,具有足够的无瘤边缘和最小的手术发病率,并指出手术治愈了约 45% 的患者,而化疗和放疗仅治愈了 5% 的患者。在肺癌、乳腺癌、前列腺癌、结肠癌和胰腺癌中,与部分或不完全手术切除相比,完全切除肿瘤的生存率可提高 3 至 5 倍。然而,术中对肿瘤边缘的评估仅基于触诊和目视检查,经常导致肿瘤切除不完全(R1切除)。目标是开发用于肿瘤外科“观察和治疗”模式的纳米技术,通过聚合物胶束发射组织穿透近红外光来描绘肿瘤边缘和手术指导;术中光动力治疗 (PDT) 时产生单线态氧;并通过共同递送棉酚来增强癌细胞凋亡,棉酚是一种天然的 BH3 模拟物,可抑制抗凋亡 Bcl-2 蛋白:Bcl-2、Bcl-xL 和 Mcl-1。我们已经证明,聚(乙二醇)-嵌段聚(ε-己内酯)(PEG-b-PCL)组装成纳米颗粒,夹带近红外染料(DiR)、光敏剂(mTHPP)和棉酚,形成胶束直径为 100 nm,可在 24 小时内缓慢释放所有 3 种成分。我们假设填充有 DiR、mTHPP 和棉酚的 PEG-b-PCL 胶束将通过增强的渗透性和保留效应在实体瘤处积聚并“照亮”肿瘤边缘,从而实现手术引导、更完整的手术切除和更低的肿瘤复发。我们假设,传递到肿瘤床“照亮”区域(术中 PDT)的激光将产生杀死肿瘤细胞的单线态氧,特别是与共同传递的棉酚配合使用。具体目的:(1)通过体外物理化学和光物理研究以及体内实验:全身光学成像来评估填充有DiR、mTHPP和棉酚的PEG-b-PCL胶束的稳定性、单线态氧的产生和肿瘤靶向性DiR 和 mTHPP 的研究以及棉酚的药代动力学研究。 (2)。评估用 DiR 填充的 PEG-b-PCL 胶束进行手术引导和手术切除肿瘤后以及仅手术切除肿瘤后作为阳性对照的肿瘤复发情况。 (3)。评估手术切除和术中 PDT 后肿瘤的复发情况,使用填充有 mTHPP 的 PEG-b-PCL 胶束(含或不含共掺棉酚)。 (4)。评估 DiR 光学成像、手术切除以及术中使用 mTHPP 和棉酚进行 PDT(三模式疗法)后肿瘤的复发情况。生物相容性 PEG-b-PCL 胶束的集成光学成像和治疗能力的进步将使纳米技术在外科肿瘤学中的应用成为可能,并快速转化为临床试验。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
Thermosensitive poly-(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly-(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery.
用于多药物递送的热敏聚-(d,L-丙交酯-共-乙交酯)-嵌段-聚(乙二醇)-嵌段-聚-(d,L-丙交酯-共-乙交酯)水凝胶。
- DOI:
- 发表时间:2014-08
- 期刊:
- 影响因子:4.5
- 作者:Cho, Hyunah;Kwon, Glen S
- 通讯作者:Kwon, Glen S
Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance.
用于癌症凋亡靶向光学成像和术中手术指导的聚合物胶束。
- DOI:
- 发表时间:2014
- 期刊:
- 影响因子:3.7
- 作者:Cho, Hyunah;Cho, Clifford S;Indig, Guilherme L;Lavasanifar, Afsaneh;Vakili, Mohammad Reza;Kwon, Glen S
- 通讯作者:Kwon, Glen S
Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging.
用于新辅助癌症治疗和肿瘤引发光学成像的聚合物胶束。
- DOI:10.1021/nn202676u
- 发表时间:2011-11-22
- 期刊:
- 影响因子:17.1
- 作者:Cho H;Kwon GS
- 通讯作者:Kwon GS
Triolimus: A Multi-Drug Loaded Polymeric Micelle Containing Paclitaxel, 17-AAG, and Rapamycin as a Novel Radiosensitizer.
Triolimus:一种载有多种药物的聚合物胶束,含有紫杉醇、17-AAG 和雷帕霉素,作为新型放射增敏剂。
- DOI:10.1002/mabi.201600194
- 发表时间:2017-01
- 期刊:
- 影响因子:4.6
- 作者:Tomoda K;Tam YT;Cho H;Buehler D;Kozak KR;Kwon GS
- 通讯作者:Kwon GS
Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.
用于组合药物递送的聚(乙二醇)-块-聚(ε-己内酯)胶束:在卵巢癌腹膜内异种移植模型中评估紫杉醇、环巴明和棉酚。
- DOI:10.1016/j.jconrel.2012.12.005
- 发表时间:2013-02-28
- 期刊:
- 影响因子:0
- 作者:Cho H;Lai TC;Kwon GS
- 通讯作者:Kwon GS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Glen S. Kwon其他文献
"Block Copolymer Synthesis of Nanoscale Drug and Gene Delivery", in Nanotechnology in Drug Delivery
“纳米级药物和基因递送的嵌段共聚物合成”,药物递送纳米技术
- DOI:
- 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
Glen S. Kwon - 通讯作者:
Glen S. Kwon
[64Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis
[64Cu]Cu-PEG-FUD 肽用于无创、灵敏地检测小鼠肺纤维化
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:13.6
- 作者:
Hye Jin Lee;K. Bernau;T. Harr;Z. Rosenkrans;Grace A. Kessler;Kristen Stott;A. Oler;Babita Rahar;Terry Zhu;Y. Medina;Nikesh Gupta;Inyoung Cho;Metti K Gari;B. Burkel;Justin J. Jeffery;Ashley M. Weichmann;Bianca R. Tomasini;S. Ponik;Jonathan W. Engle;Reinier Hernandez;Glen S. Kwon;N. Sandbo - 通讯作者:
N. Sandbo
Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B.
用于药物递送的聚合物胶束:两性霉素 B 的增溶和溶血活性。
- DOI:
10.1016/s0168-3659(97)00245-9 - 发表时间:
1998-04-30 - 期刊:
- 影响因子:0
- 作者:
B. Yu;T. Okano;Kazunori Kataoka;Glen S. Kwon - 通讯作者:
Glen S. Kwon
Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery.
将质粒 DNA 封装在可生物降解的聚(D,L-乳酸-乙醇酸)微球中作为免疫基因递送的新方法。
- DOI:
10.1016/s0168-3659(98)00099-6 - 发表时间:
1999-09-14 - 期刊:
- 影响因子:0
- 作者:
Daqing Wang;Deborah R. Robinson;Glen S. Kwon;John Samuel - 通讯作者:
John Samuel
Use of a liposome antigen delivery system to alter immune responses in vivo.
使用脂质体抗原递送系统改变体内免疫反应。
- DOI:
10.1021/js980075p - 发表时间:
1998-11-01 - 期刊:
- 影响因子:3.8
- 作者:
Christine M. E. Lutsiak;Deborah Sosnowski;David S. Wishart;Glen S. Kwon;Glen S. Kwon;John Samuel;John Samuel - 通讯作者:
John Samuel
Glen S. Kwon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Glen S. Kwon', 18)}}的其他基金
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
用于联合治疗的寡(乳酸)n-前药纳米药物
- 批准号:
10371257 - 财政年份:2021
- 资助金额:
$ 17.47万 - 项目类别:
Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly
使用纤连蛋白组装的有效抑制剂对肿瘤微环境进行直接治疗干预
- 批准号:
10409814 - 财政年份:2021
- 资助金额:
$ 17.47万 - 项目类别:
Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly
使用纤连蛋白组装的有效抑制剂对肿瘤微环境进行直接治疗干预
- 批准号:
10199263 - 财政年份:2021
- 资助金额:
$ 17.47万 - 项目类别:
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
用于联合治疗的寡聚(乳酸)n-前药纳米药物
- 批准号:
10597075 - 财政年份:2021
- 资助金额:
$ 17.47万 - 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
- 批准号:
8497027 - 财政年份:2013
- 资助金额:
$ 17.47万 - 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
- 批准号:
8786047 - 财政年份:2013
- 资助金额:
$ 17.47万 - 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
- 批准号:
8605161 - 财政年份:2013
- 资助金额:
$ 17.47万 - 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
- 批准号:
8605161 - 财政年份:2013
- 资助金额:
$ 17.47万 - 项目类别:
Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology
用于“See”的三峰聚合物胶束
- 批准号:
8175145 - 财政年份:2011
- 资助金额:
$ 17.47万 - 项目类别:
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY
用于药物输送的生物特异性聚合物酶缀合物
- 批准号:
6626768 - 财政年份:2001
- 资助金额:
$ 17.47万 - 项目类别:
相似国自然基金
RIPK1泛素化修饰介导MLKL调控隐窝基底柱状细胞坏死性凋亡在脓毒症肠损伤中的机制研究
- 批准号:82302477
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
局灶节段硬化性肾小球肾炎中FSTL3通过DC-SIGN促足细胞凋亡的作用研究
- 批准号:82300796
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Foxo3通过ROS介导的氧化应激和凋亡双向调控和厚朴酚神经效-毒作用的机制研究
- 批准号:82304639
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
凋亡小体通过ACKR3介导巨噬细胞重编程对狼疮的疗效及机制研究
- 批准号:82302053
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SIRT2/Annexin A2/autophagy通路形成的分子机制及其在HCC细胞失巢凋亡抵抗中的作用研究
- 批准号:32300626
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Targeted neuroendocrine cancer therapy using Verrucarin A
使用 Verrucarin A 进行靶向神经内分泌癌症治疗
- 批准号:
10356245 - 财政年份:2021
- 资助金额:
$ 17.47万 - 项目类别:
Targeted neuroendocrine cancer therapy using Verrucarin A
使用 Verrucarin A 进行靶向神经内分泌癌症治疗
- 批准号:
10538603 - 财政年份:2021
- 资助金额:
$ 17.47万 - 项目类别:
Optimizing the therapeutic index for pediatric medulloblastomas by targeting apoptosis
通过靶向细胞凋亡优化儿童髓母细胞瘤的治疗指数
- 批准号:
10316157 - 财政年份:2020
- 资助金额:
$ 17.47万 - 项目类别: